Hikal earns EcoVadis Gold for sustainability performance
NiveshIQ
NSE: HIKAL
Hikal Ltd.
₹216.99▼ ₹4.39 (-1.98%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on HIKAL. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Hikal Ltd.
Hikal Limited is a leading Indian healthcare company specializing in the manufacture and sale of chemical intermediates, specialty chemicals, and active pharma ingredients to various industries. The company operates through two key segments: Pharmaceuticals and Crop Protection, with a strong presence in the production of pesticides and herbicides. Hikal has recently commissioned a cGMP pilot plant at its Pune research campus, aimed at accelerating pharmaceutical development and innovation. This strategic move is expected to enhance the company's competitiveness and growth prospects. With a revenue of ₹1204 Cr and net income of ₹74 Cr, Hikal has demonstrated its ability to deliver stable financial performance. The company's commitment to sustainability is also evident, having earned EcoVadi
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,785 Cr -11.80% | ₹1,860 Cr +4.20% | ₹1,713 Cr -7.90% |
| EBITDA Margin | 14.96% | 17.63% | 13.59% |
| Net Profit | ₹70.00 Cr -10.30% | ₹91.00 Cr +30.00% | -153.60% |
| EPS | ₹5.64 | ₹7.37 | ₹-3.96 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Hikal Ltd Technical Momentum Shifts Amid Mixed Market Signals
Watch Hikal vs. Castellano: Fight Highlights Live Stream Online | DAZN IN
🔒
+ 3 more stories about Hikal Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹403 Cr, PAT ₹-7 Cr, EPS ₹-0.60, EBITDA margin 9.6%. Growth context: revenue YoY +15.2%, revenue QoQ -22.4%, PAT QoQ -151.4%.
Management commentary highlights the company's focus on product launches, approvals, and therapy-mix improvement, as wel...
FY26 (last completed FY): revenue ₹1, 713 Cr, PAT ₹-49 Cr, EBITDA margin 13.6%, EPS ₹-3.96. Year-on-year: revenue YoY -7...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for HIKAL
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track HIKAL alongside your other holdings
Unlock full HIKAL research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Hikal Ltd.?
NiveshIQ detects active intelligence signals for Hikal Ltd. (HIKAL) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Hikal Ltd.?
Hikal Ltd. is listed on NSE/BSE with a market capitalisation of ₹267,550.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.